Skip to main content

Advertisement

SpringerLink
Log in

Prevention of post liver transplant HBV recurrence

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Background

Twenty years ago, liver transplantation for hepatitis B had been a relative contraindication to universal HBV recurrence and poor outcomes. Over the ensuing two decades, there has been refinement of prevention strategies in order to minimize HBV recurrence in the allograft.

Results

Currently, the most efficacious and cost-effective strategies include newer oral antiviral drugs in combination with low doses of hepatitis B immunoglobulin (HBIG). More recently, strategies have been successful in withdrawing HBIG and newer approaches of HBIG avoidance are currently under development.

Conclusion

Thus, 20 years afterward, HBV recurrence is <5% and outcomes following liver transplantation are excellent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61:362–326

    Article  PubMed  CAS  Google Scholar 

  2. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817–823

    PubMed  Google Scholar 

  3. Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl 2008;14:S23–S26

    Article  PubMed  Google Scholar 

  4. Degertekin B, Han SH, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 1823;10:1823–1833

    Article  Google Scholar 

  5. Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; (1):6–12

  6. Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. Liver Transpl 2008;14:S1–S7

    Article  PubMed  Google Scholar 

  7. Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003;9:49–56

    Article  PubMed  Google Scholar 

  8. Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411–416

    Article  PubMed  CAS  Google Scholar 

  9. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207–210

    Article  PubMed  CAS  Google Scholar 

  10. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719–727

    Article  PubMed  Google Scholar 

  11. Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl 2008;14:S8–S14

    Article  PubMed  Google Scholar 

  12. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–1531

    Article  PubMed  CAS  Google Scholar 

  13. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349–360

    Article  PubMed  Google Scholar 

  14. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419–1427

    PubMed  CAS  Google Scholar 

  15. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218–1229

    Article  PubMed  CAS  Google Scholar 

  16. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62–72

    Article  PubMed  CAS  Google Scholar 

  17. Garg H, Sarin SK, Kumar M, et al. (2011) Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology

  18. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2009;52:176–182

    Article  PubMed  Google Scholar 

  19. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50(6):2001–2016

    Article  PubMed  CAS  Google Scholar 

  20. Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54(2):236–242

    Article  PubMed  CAS  Google Scholar 

  21. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. (2011) Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized open-label study. Hepatology

  22. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813–815

    Article  PubMed  CAS  Google Scholar 

  23. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842–1847

    Article  PubMed  CAS  Google Scholar 

  24. Angus PW, Locarnini SA, McCaughan GW, et al. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995;21:14–18

    Article  Google Scholar 

  25. McMillan JS, Bowden DS, Angus PW, et al. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 1996;24:1371–1378

    Article  PubMed  CAS  Google Scholar 

  26. Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999;30:715–721

    Article  PubMed  CAS  Google Scholar 

  27. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212–1215

    Article  PubMed  CAS  Google Scholar 

  28. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424–432

    Article  PubMed  CAS  Google Scholar 

  29. Lo CM, Fung JT, Lau GK, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003;37:36–43

    Article  PubMed  CAS  Google Scholar 

  30. Luo Y, Lo CM, Cheung CK, et al. Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl 2007;13:71–79

    Article  PubMed  Google Scholar 

  31. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585–589

    Article  PubMed  CAS  Google Scholar 

  32. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903–910

    Article  PubMed  CAS  Google Scholar 

  33. Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6(6):741–748

    Article  PubMed  CAS  Google Scholar 

  34. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429–433

    Article  PubMed  CAS  Google Scholar 

  35. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931–937

    Article  PubMed  CAS  Google Scholar 

  36. Karademir S, Astarcioglu H, Akarsu M, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006;38:579–583

    Article  PubMed  CAS  Google Scholar 

  37. Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007;83:231–233

    Article  PubMed  CAS  Google Scholar 

  38. Nath DS, Kalis A, Nelson S, et al. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006;20:206–210

    Article  PubMed  Google Scholar 

  39. Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460–1466

    Article  PubMed  CAS  Google Scholar 

  40. Saab S, Desai S, Tsaoi D, et al. Posttransplantation Hepatitis B Prophylaxis with Combination Oral Nucleoside and Nucleotide Analog Therapy. Am J Transplant 2011;7:1600–6143

    Google Scholar 

  41. Cheung CK, Lo CM, Man K, et al. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 2010;16:1314–1323

    Article  PubMed  Google Scholar 

  42. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002;35(1):176–181

    Article  PubMed  Google Scholar 

  43. Bienzle U, Gunther M, Neuhaus R, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003;38:811–819

    PubMed  CAS  Google Scholar 

  44. Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005;43:283–287

    Article  PubMed  CAS  Google Scholar 

  45. Wadhawan M, Gupta S, Vij V, et al. Living related liver transplant (LRLT) in HBV DNA negative cirrhosis without hepatitis B immunoglobulin (HBIG). Hepatol Int 2011;5:38

    Google Scholar 

  46. Saab S, Waterman B, Chi AC, et al. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl 2010;16:300–307

    PubMed  Google Scholar 

  47. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010;52:272–279

    Article  PubMed  CAS  Google Scholar 

  48. Pascarella S, Negro F, Hepatitis D. virus: an update. Liver Int 2010;31:7–21

    Article  PubMed  Google Scholar 

  49. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322–331

    Article  PubMed  CAS  Google Scholar 

  50. Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995;21:333–339

    Article  PubMed  CAS  Google Scholar 

  51. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008;134:1890–1899 (quiz 2155)

    Google Scholar 

  52. Saab S, Yeganeh M, Nguyen K, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009;15:1525–1534

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The AW Morrow Gastroenterology and Liver Centre, The Centenary Research Institute, Royal Prince Alfred Hospital and The University of Sydney, Missenden Road, Camperdown, NSW, 2050, Australia

    Geoffrey W. McCaughan

Authors
  1. Geoffrey W. McCaughan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey W. McCaughan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCaughan, G.W. Prevention of post liver transplant HBV recurrence. Hepatol Int 5, 876–881 (2011). https://doi.org/10.1007/s12072-011-9293-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-011-9293-8

Keywords

Search

Navigation